Georg Winterer1. 1. Department of Psychiatry, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany. georg.winterer@uni-duesseldorf.de
Abstract
PURPOSE OF REVIEW: Among the mentally ill, smoking prevalence is highest in patients with schizophrenia ( approximately 70-80%). This can impose a significant financial burden on patients, not to speak of increased smoking-related morbidity and mortality. Therefore, it is critical for clinicians to understand why patients with schizophrenia smoke in order to adapt treatment schemes. Understanding the reasons may also help to develop new drugs that target the nicotinic system in the brain as well as smoking cessation programs that are specifically designed for this particular patient population. RECENT FINDINGS: So far, several reasons have been identified which are believed to explain tobacco consumption in patients with schizophrenia. Originally, it was widely believed that patients with schizophrenia smoke to increase hepatic clearance and to restore the dopamine blockade of certain antipsychotic drugs to diminish their side effects. However, more recently it became obvious that cigarette smoking may also be reinforcing for patients because it improves psychiatric symptoms, most notably negative and cognitive symptoms. The underlying molecular mechanisms of these nicotine effects are currently under intensive investigation. SUMMARY: Heavy smoking in schizophrenia cannot simply be viewed as a 'bad habit'. Rather, self-medication of clinical symptoms and side effects of antipsychotic drugs appear to play a major role.
PURPOSE OF REVIEW: Among the mentally ill, smoking prevalence is highest in patients with schizophrenia ( approximately 70-80%). This can impose a significant financial burden on patients, not to speak of increased smoking-related morbidity and mortality. Therefore, it is critical for clinicians to understand why patients with schizophrenia smoke in order to adapt treatment schemes. Understanding the reasons may also help to develop new drugs that target the nicotinic system in the brain as well as smoking cessation programs that are specifically designed for this particular patient population. RECENT FINDINGS: So far, several reasons have been identified which are believed to explain tobacco consumption in patients with schizophrenia. Originally, it was widely believed that patients with schizophrenia smoke to increase hepatic clearance and to restore the dopamine blockade of certain antipsychotic drugs to diminish their side effects. However, more recently it became obvious that cigarette smoking may also be reinforcing for patients because it improves psychiatric symptoms, most notably negative and cognitive symptoms. The underlying molecular mechanisms of these nicotine effects are currently under intensive investigation. SUMMARY: Heavy smoking in schizophrenia cannot simply be viewed as a 'bad habit'. Rather, self-medication of clinical symptoms and side effects of antipsychotic drugs appear to play a major role.
Authors: Suzanne Lo; Stephen J Heishman; Heather Raley; Katherine Wright; Heidi J Wehring; Eric T Moolchan; Stephanie Feldman; Fang Liu; Robert P McMahon; Charles M Richardson; Deanna L Kelly Journal: Schizophr Res Date: 2010-07-15 Impact factor: 4.939
Authors: C Quisenaerts; M Morrens; W Hulstijn; E de Bruijn; M Timmers; J Streffer; J De la Asuncion; G Dumont; B Sabbe Journal: Psychopharmacology (Berl) Date: 2014-02 Impact factor: 4.530
Authors: Jason Smucny; Korey P Wylie; Eugene Kronberg; Kristina T Legget; Jason R Tregellas Journal: J Psychiatr Res Date: 2017-02-03 Impact factor: 4.791
Authors: Anne Schmechtig; Jane Lees; Lois Grayson; Kevin J Craig; Rukiya Dadhiwala; Gerard R Dawson; J F William Deakin; Colin T Dourish; Ivan Koychev; Katrina McMullen; Ellen M Migo; Charlotte Perry; Lawrence Wilkinson; Robin Morris; Steve C R Williams; Ulrich Ettinger Journal: Psychopharmacology (Berl) Date: 2013-02-22 Impact factor: 4.530
Authors: S de la Salle; D Smith; J Choueiry; D Impey; T Philippe; H Dort; A Millar; P Albert; V Knott Journal: Neuroscience Date: 2013-03-25 Impact factor: 3.590